vs
Side-by-side financial comparison of Sila Realty Trust, Inc. (SILA) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $50.1M, roughly 1.9× Sila Realty Trust, Inc.). Vericel Corp runs the higher net margin — 25.0% vs 10.0%, a 15.0% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs 7.6%). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs -0.6%).
Sila Realty Trust, Inc. is a U.S.-based real estate investment trust that owns, operates, and acquires high-quality income-generating commercial properties. Its core portfolio covers industrial logistics facilities, office assets and mixed-use properties, serving tenants across logistics, corporate and retail segments to deliver stable long-term returns.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
SILA vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $50.1M | $92.9M |
| Net Profit | $5.0M | $23.2M |
| Gross Margin | 88.9% | 78.7% |
| Operating Margin | — | 24.1% |
| Net Margin | 10.0% | 25.0% |
| Revenue YoY | 7.6% | 23.3% |
| Net Profit YoY | -54.9% | 17.3% |
| EPS (diluted) | $0.10 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $50.1M | $92.9M | ||
| Q3 25 | $49.8M | $67.5M | ||
| Q2 25 | $48.7M | $63.2M | ||
| Q1 25 | $48.3M | $52.6M | ||
| Q4 24 | $46.5M | $75.4M | ||
| Q3 24 | $46.1M | $57.9M | ||
| Q2 24 | $43.6M | $52.7M | ||
| Q1 24 | $50.6M | $51.3M |
| Q4 25 | $5.0M | $23.2M | ||
| Q3 25 | $11.6M | $5.1M | ||
| Q2 25 | $8.6M | $-553.0K | ||
| Q1 25 | $7.9M | $-11.2M | ||
| Q4 24 | $11.1M | $19.8M | ||
| Q3 24 | $11.9M | $-901.0K | ||
| Q2 24 | $4.6M | $-4.7M | ||
| Q1 24 | $15.0M | $-3.9M |
| Q4 25 | 88.9% | 78.7% | ||
| Q3 25 | 88.1% | 73.5% | ||
| Q2 25 | 87.7% | 73.7% | ||
| Q1 25 | 86.9% | 69.0% | ||
| Q4 24 | 87.3% | 77.6% | ||
| Q3 24 | 87.4% | 71.9% | ||
| Q2 24 | 86.6% | 69.5% | ||
| Q1 24 | 89.0% | 68.9% |
| Q4 25 | — | 24.1% | ||
| Q3 25 | — | 5.1% | ||
| Q2 25 | — | -3.2% | ||
| Q1 25 | — | -24.3% | ||
| Q4 24 | — | 24.5% | ||
| Q3 24 | — | -4.3% | ||
| Q2 24 | — | -11.5% | ||
| Q1 24 | — | -10.7% |
| Q4 25 | 10.0% | 25.0% | ||
| Q3 25 | 23.3% | 7.5% | ||
| Q2 25 | 17.6% | -0.9% | ||
| Q1 25 | 16.4% | -21.4% | ||
| Q4 24 | 23.9% | 26.3% | ||
| Q3 24 | 25.9% | -1.6% | ||
| Q2 24 | 10.6% | -8.9% | ||
| Q1 24 | 29.6% | -7.5% |
| Q4 25 | $0.10 | $0.46 | ||
| Q3 25 | $0.21 | $0.10 | ||
| Q2 25 | $0.15 | $-0.01 | ||
| Q1 25 | $0.14 | $-0.23 | ||
| Q4 24 | $0.20 | $0.40 | ||
| Q3 24 | $0.21 | $-0.02 | ||
| Q2 24 | $0.08 | $-0.10 | ||
| Q1 24 | $0.26 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $32.3M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $354.6M |
| Total Assets | $2.1B | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.3M | $137.5M | ||
| Q3 25 | $27.7M | $135.4M | ||
| Q2 25 | $24.8M | $116.9M | ||
| Q1 25 | $30.5M | $112.9M | ||
| Q4 24 | $39.8M | $116.2M | ||
| Q3 24 | $28.6M | $101.7M | ||
| Q2 24 | $87.0M | $102.5M | ||
| Q1 24 | $90.2M | $110.6M |
| Q4 25 | $1.3B | $354.6M | ||
| Q3 25 | $1.3B | $321.9M | ||
| Q2 25 | $1.4B | $306.8M | ||
| Q1 25 | $1.4B | $295.5M | ||
| Q4 24 | $1.4B | $292.0M | ||
| Q3 24 | $1.4B | $257.5M | ||
| Q2 24 | $1.5B | $243.0M | ||
| Q1 24 | $1.5B | $233.9M |
| Q4 25 | $2.1B | $488.0M | ||
| Q3 25 | $2.1B | $453.3M | ||
| Q2 25 | $2.0B | $435.6M | ||
| Q1 25 | $2.0B | $424.6M | ||
| Q4 24 | $2.0B | $432.7M | ||
| Q3 24 | $2.0B | $390.4M | ||
| Q2 24 | $2.1B | $376.8M | ||
| Q1 24 | $2.1B | $356.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $119.1M | $15.0M |
| Free Cash FlowOCF − Capex | — | $12.8M |
| FCF MarginFCF / Revenue | — | 13.8% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | 23.76× | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | — | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $119.1M | $15.0M | ||
| Q3 25 | $30.0M | $22.1M | ||
| Q2 25 | $31.9M | $8.2M | ||
| Q1 25 | $24.1M | $6.6M | ||
| Q4 24 | $132.8M | $22.2M | ||
| Q3 24 | $29.1M | $10.2M | ||
| Q2 24 | $31.6M | $18.5M | ||
| Q1 24 | $36.6M | $7.2M |
| Q4 25 | — | $12.8M | ||
| Q3 25 | — | $19.5M | ||
| Q2 25 | — | $81.0K | ||
| Q1 25 | — | $-7.6M | ||
| Q4 24 | — | $8.5M | ||
| Q3 24 | — | $-9.2M | ||
| Q2 24 | — | $1.8M | ||
| Q1 24 | — | $-6.8M |
| Q4 25 | — | 13.8% | ||
| Q3 25 | — | 28.8% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | -14.5% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | -15.9% | ||
| Q2 24 | — | 3.4% | ||
| Q1 24 | — | -13.3% |
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | — | 12.9% | ||
| Q1 25 | — | 27.0% | ||
| Q4 24 | — | 18.3% | ||
| Q3 24 | — | 33.5% | ||
| Q2 24 | — | 31.8% | ||
| Q1 24 | — | 27.3% |
| Q4 25 | 23.76× | 0.65× | ||
| Q3 25 | 2.59× | 4.35× | ||
| Q2 25 | 3.71× | — | ||
| Q1 25 | 3.06× | — | ||
| Q4 24 | 11.95× | 1.12× | ||
| Q3 24 | 2.43× | — | ||
| Q2 24 | 6.84× | — | ||
| Q1 24 | 2.44× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SILA
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
